Asset Details
Do you wish to reserve the book?
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
Do you wish to request the book?
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
2013
Overview
Background:
Potential drug–drug interactions (PDDIs) in patients with cancer are common, but have not previously been quantified for oral anticancer treatment. We assessed the prevalence and seriousness of potential PDDIs among ambulatory cancer patients on oral anticancer treatment.
Methods:
A search was conducted in a computer-based medication prescription system for dispensing oral anticancer drugs to outpatients in three Dutch centres. Potential drug–drug interactions were identified using electronic (Drug Interaction Fact software) and manual screening methods (peer-reviewed reports).
Results:
In the 898 patients included in the study, 1359 PDDIs were identified in 426 patients (46%, 95% confidence interval (CI)=42–50%). In 143 patients (16%), a major PDDI was identified. The drug classes most frequently involved in a major PDDI were coumarins and opioids. The majority of cases concerned central nervous system interactions, PDDIs that can cause gastrointestinal toxicity and prolongation of QT intervals. In multivariate analysis, concomitant use of more drugs (odds ratio (OR)=1.66, 95% CI=1.54–1.78,
P
<0001) and genito-urinary cancer (OR=0.25, 95% CI=0.12–0.52,
P
<0001) were risk factors.
Conclusion:
Potential drug–drug interactions are very common among cancer patients on oral cancer therapy. Physicians and pharmacists should be more aware of these potential interactions.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - adverse effects
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Drug Administration Schedule
/ Enzymes
/ Female
/ Humans
/ Male
/ Oncology
/ Otorhinolaryngology. Stomatology
/ Patients
/ Tumors
